Literature DB >> 20652657

An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial.

Diana Rofail1, Muriel Viala, Adam Gater, Linda Abetz-Webb, Jean-Francois Baladi, Maria Domenica Cappellini.   

Abstract

INTRODUCTION: The Satisfaction with Iron Chelation Therapy (SICT) instrument was developed based on a literature review, in-depth patient and clinician interviews, and cognitive debriefing interviews. An, open-label, single arm, multicenter trial evaluating the efficacy and safety of deferasirox in patients diagnosed with transfusion-dependent iron overload, provided an opportunity to assess the psychometric measurement properties of the instrument.
METHODS: Psychometric analyses were performed using data at baseline from 273 patients with a range of transfusion-dependent iron overload conditions who were participating in a multinational study. Responsiveness was further evaluated for all patients who also had subsequent satisfaction domain scores collected at week 4.
RESULTS: Baseline SICT domain scores had acceptable floor and ceiling effects and internal consistency reliability (Cronbach's alpha: 0.75-0.85). Item discriminant and item convergent validity were both excellent although one item in each analysis did not meet the specified criterion. Small to moderate correlations were observed between SICT and Short Form 36 Health Survey (SF-36) domain scores. Patients with the highest levels of serum ferritin at baseline (>3100 ng/mL) were the least satisfied about the Perceived Effectiveness of ICT and vice versa. Satisfaction improved in all patients, although there were no clear differences observed between groups of patients defined according to changes in serum ferritin levels from baseline to week 4 (stable, improved, or worsened).
CONCLUSIONS: The SICT domains are reliable and valid. Further testing using a more specific criterion (such as assessing patient global ratings of change in satisfaction domains that correspond to the SICT domains) could help to establish with greater confidence the responsiveness of the instrument.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652657     DOI: 10.1007/s12325-010-0049-y

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

Review 1.  Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

Authors:  Patricia M Fortin; Karen V Madgwick; Marialena Trivella; Sally Hopewell; Carolyn Doree; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09

Review 2.  Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

Authors:  Patricia M Fortin; Sheila A Fisher; Karen V Madgwick; Marialena Trivella; Sally Hopewell; Carolyn Doree; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-08

3.  Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.

Authors:  Sefika Pinar Senol; Eyup Naci Tiftik; Selma Unal; Aydan Akdeniz; Bahar Tasdelen; Bahar Tunctan
Journal:  J Basic Clin Pharm       Date:  2016-03

4.  Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial.

Authors:  John Porter; Donald K Bowden; Marina Economou; Jacques Troncy; Arnold Ganser; Dany Habr; Nicolas Martin; Adam Gater; Diana Rofail; Linda Abetz-Webb; Helen Lau; Maria Domenica Cappellini
Journal:  Anemia       Date:  2012-08-12

Review 5.  Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?

Authors:  Tang-Her Jaing
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

6.  Development of the Thalassaemia Adult Life Index (ThALI).

Authors:  Xenya Kantaris; Mark Shevlin; John Porter; Lynn Myers
Journal:  Health Qual Life Outcomes       Date:  2020-06-12       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.